| IQV |
Report |
Total Revenue (Q2 2026) |
BEAT |
pred ~$4.34B vs. cons $4.30B |
MEDIUM |
| IQV |
Report |
Adjusted Diluted EPS (Q2 2026) |
BEAT |
pred ~$3.10 vs. cons $3.01 |
MEDIUM |
| IQV |
Report |
R&DS Book-to-Bill Ratio |
BEAT |
pred ~1.10x vs. implied street expectation ~1.05x |
LOW |
| IQV |
Guide |
FY2026 Revenue Guidance |
BETTER |
guide ~$17.30B (narrow raise/reaffirm at top of $17.15-17.35B range) vs. cons $17.30B (FY2026) |
MEDIUM |
| IQV |
Guide |
FY2026 Adjusted Diluted EPS Guidance |
BETTER |
guide ~$12.90 (raised range, e.g. $12.80-$13.00) vs. cons $12.80 (FY2026) |
MEDIUM |
| IQV |
Guide |
Q3 2026 Revenue Guidance (implied next-Q) |
BETTER |
guide ~$4.40B vs. cons ~$4.38B (Q3 2026) |
LOW |
| IQV |
Return |
Day-1 residual (stock − beta × S&P 500) |
+2.5% |
— |
MEDIUM |
| IQV |
Return |
5-day cumulative residual |
+1.0% (FADE) |
IQV has a strong beat-and-raise history into this print (4 straight EPS beats, avg ~1.6% surprise; FY26 EPS guide already raised once in Q1), so a modest top/bottom-line beat and another small guidance nudge look likely, supporting a positive day-1 pop. But the stock already rallied ~36% off its April low and ~7% in the week before the print, meaning much of the 'oversold reversion' and raise optimism is pre-positioned — unlike last year's Q2 print (+14.7%) or this year's Q1 print (+9.6%), both of which came after sharp pre-earnings drawdowns. In both of those precedents the initial pop faded over the following 2-3 weeks as investors digested that the raise was largely incremental rather than a structural re-rating, and as book-to-bill/bookings-mix noise and lingering large-pharma/policy uncertainty reasserted. With less 're-rating' runway left this time, expect a similar partial giveback of the day-1 gain over the next week rather than continued follow-through. |
MEDIUM |